Business Context and Reporting Period
Company: Tonix Pharmaceuticals Holding Corp.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2018
Business Overview: Tonix is a clinical-stage biopharmaceutical company focused on developing treatments for neuropsychiatric conditions and biodefense countermeasures. The company has no commercial products and generates no revenue. Its primary focus is the development of Tonmya (TNX-102 SL), a sublingual cyclobenzaprine formulation for Posttraumatic Stress Disorder (PTSD), which is currently in Phase 3 development. Other pipeline candidates include TNX-102 SL for Fibromyalgia and Agitation in Alzheimer's Disease, TNX-601 (tianeptine oxalate) for PTSD, and TNX-801 (a smallpox vaccine candidate).
Key Financial Metrics
| Metric | 2018 | 2017 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(26.1) million | $(21.1) million |
| Operating Loss | $(26.3) million | $(21.3) million |
| Research & Development Expenses | $17.6 million | $13.3 million |
| General & Administrative Expenses | $8.8 million | $8.0 million |
| Cash and Cash Equivalents (End of Period) | $25.0 million | $25.5 million |
| Working Capital | $23.4 million | $24.3 million |
| Net Cash Used in Operating Activities | $(24.0) million | $(19.1) million |
| Net Cash Provided by Financing Activities | $23.5 million | $18.5 million |
Note: The company reported a one-time non-cash deemed dividend of $3.3 million in 2018 related to a beneficial conversion feature on Series A Convertible Preferred Stock, which increased the net loss available to common stockholders.
Material Changes vs. Prior Period
- Increased Operating Loss: Net loss increased by approximately $5.0 million (24%) year-over-year, driven primarily by higher R&D costs associated with the Phase 3 PTSD program.
- R&D Expense Growth: R&D expenses rose by $4.3 million (32%), attributed to clinical and manufacturing costs for the PTSD program.
- Financing Activity: The company raised approximately $23.5 million in net proceeds during 2018 through an underwritten public offering (December 2018), an At-the-Market (ATM) offering, and sales under a purchase agreement with Lincoln Park Capital. This contrasts with $18.5 million raised in 2017.
- Stock Split: A 1-for-10 reverse stock split was effected on November 28, 2018.
- Going Concern Warning: The independent auditor issued a report with an explanatory paragraph expressing substantial doubt about the company's ability to continue as a going concern due to recurring losses and negative cash flows, noting that resources are insufficient to meet operating requirements for the one-year period following the filing date.
Guidance, Outlook, and Risks
Clinical Development Updates
- PTSD (Tonmya): The Phase 3 HONOR study was discontinued after an interim analysis failed to meet a pre-defined threshold for continuing enrollment. However, retrospective analysis identified a treatment effect in patients with trauma occurring within 9 years of screening. A new Phase 3 study, RECOVERY, was initiated in Q1 2019 with a design restricted to this 9-year window. Topline data is expected in the first half of 2020.
- Regulatory Status: The FDA rescinded the Breakthrough Therapy Designation (BTD) for Tonmya in March 2019 due to the HONOR study results. The company maintains that this does not alter its development plan.
- Fibromyalgia: Development was paused in 2016 following the Phase 3 AFFIRM study results (which missed the primary endpoint but showed significance on secondary endpoints). The program was re-initiated in 2019 to pursue a higher dose (5.6 mg) based on PTSD data.
- Alzheimer's Agitation: TNX-102 SL received Fast Track designation from the FDA in July 2018.
Outlook and Liquidity
Management believes cash resources are sufficient to fund operations through the end of 2019 but explicitly states they do not have enough resources to meet operating requirements for the one-year period from the date of filing. The company anticipates needing additional capital to fund future clinical trials and operations. Failure to secure funding could force delays or elimination of R&D programs.
Key Risks
- Capital Requirements: Substantial doubt exists regarding the ability to continue as a going concern without additional financing.
- Clinical Failure: Success depends entirely on the successful completion of the RECOVERY study and subsequent regulatory approval. Previous Phase 3 studies (HONOR and AFFIRM) faced challenges.
- Regulatory Uncertainty: The company relies on Section 505(b)(2) NDAs, which may require additional data or face patent litigation delays.
- Competition: Intense competition exists in the PTSD and CNS therapeutic areas from large pharmaceutical companies and other biotechs.
Important Facts for Investor Verification
- Going Concern Status: Verify the company's ability to raise additional capital, as the auditor has flagged substantial doubt about its ability to continue operations beyond the near term.
- RECOVERY Study Design: Confirm the enrollment criteria (trauma within 9 years) and timeline for the new Phase 3 PTSD study, as this is the primary path to revenue.
- Patent Expiry: Review the patent portfolio for Tonmya, with key U.S. patents expiring between 2030 and 2034, to assess the potential commercial window.
- Stock Dilution: Monitor future equity issuances, as the company has a history of raising capital through stock sales, which dilutes existing shareholders.
- Breakthrough Therapy Status: Note the rescission of the Breakthrough Therapy Designation and its potential impact on FDA interaction timelines.